A Human Blood-Brain Interface Model to Study Barrier Crossings by Pathogens or Medicines and Their Interactions with the Brain.


Journal

Journal of visualized experiments : JoVE
ISSN: 1940-087X
Titre abrégé: J Vis Exp
Pays: United States
ID NLM: 101313252

Informations de publication

Date de publication:
09 04 2019
Historique:
entrez: 30 4 2019
pubmed: 30 4 2019
medline: 19 3 2020
Statut: epublish

Résumé

The early screening of nervous system medicines on a pertinent and reliable in cellulo BBB model for their penetration and their interaction with the barrier and the brain parenchyma is still an unmet need. To fill this gap, we designed a 2D in cellulo model, the BBB-Minibrain, by combining a polyester porous membrane culture insert human BBB model with a Minibrain formed by a tri-culture of human brain cells (neurons, astrocytes and microglial cells). The BBB-Minibrain allowed us to test the transport of a neuroprotective drug candidate (e.g., Neurovita), through the BBB, to determine the specific targeting of this molecule to neurons and to show that the neuroprotective property of the drug was preserved after the drug had crossed the BBB. We have also demonstrated that BBB-Minibrain constitutes an interesting model to detect the passage of virus particles across the endothelial cells barrier and to monitor the infection of the Minibrain by neuroinvasive virus particles. The BBB-Minibrain is a reliable system, easy to handle for researcher trained in cell culture technology and predictive of the brain cells phenotypes after treatment or insult. The interest of such in cellulo testing would be twofold: introducing derisking steps early in the drug development on the one hand and reducing the use of animal testing on the other hand.

Identifiants

pubmed: 31033945
doi: 10.3791/59220
doi:

Substances chimiques

Neuroprotective Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Video-Audio Media

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Anaelle da Costa (A)

Institut Pasteur, CNRS UMR 3569, Unité de Neuroimmunologie Virale.

Christophe Prehaud (C)

Institut Pasteur, CNRS UMR 3569, Unité de Neuroimmunologie Virale.

Florian Bakoa (F)

Institut Pasteur, CNRS UMR 3569, Unité de Neuroimmunologie Virale.

Philippe Afonso (P)

Institut Pasteur, Unité d'Epidémiologie et de Pathophysiologie des Virus Oncogènes, Université Sorbonne Paris Cité/Paris Diderot.

Pierre-Emmanuel Ceccaldi (PE)

Institut Pasteur, Unité d'Epidémiologie et de Pathophysiologie des Virus Oncogènes, Université Sorbonne Paris Cité/Paris Diderot.

Pierre Lafaye (P)

Institut Pasteur, PFIA, DTPS.

Monique Lafon (M)

Institut Pasteur, CNRS UMR 3569, Unité de Neuroimmunologie Virale; monique.lafon@pasteur.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH